<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151567</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS 010751</org_study_id>
    <secondary_id>PHRC/00-01</secondary_id>
    <secondary_id>CIC0203/004</secondary_id>
    <nct_id>NCT00151567</nct_id>
  </id_info>
  <brief_title>Evaluation of Tamsulosin in the Treatment of Ureteral Stones</brief_title>
  <acronym>TAMSULOSINE</acronym>
  <official_title>Interest of a Treatment With the alpha1-blocker Tamsulosin in the Elimination of Pelvis Ureteral Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamanouchi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ureteral stones have an important place in daily urological practice, usually causing acute
      episodes of ureteral colic by obstructing the urinary tract. The aim of the study is to
      evaluate whether repeated administration of tamsulosin, a drug routinely used in the
      treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone
      in patients with pelvis ureterolithiasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ureteral colic, mainly due to ureterolithiasis, represents 1 to 2% of hospital emergency
      admissions. When a surgical intervention is not required, usual treatment combines hydration
      and anti-inflammatory drugs.

      Alpha1-blockers, firstly developed as anti-hypertensive drugs, are now also used in the
      management of benign prostatic hyperplasia, due to their relaxing properties on the urinary
      tract. The aim of the study is to investigate whether tamsulosin could lower the delay of
      elimination of the stone in patients with pelvis ureterolithiasis. Patients are randomized to
      receive either tamsulosin or a placebo in addition to usual treatment until stone
      elimination. Efficacy is assessed by evaluating the time to spontaneous passage of the stone
      between day 1 and day 42, the need for surgery and pain recurrences.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to stone elimination in days (censored criterion)</measure>
    <time_frame>between day 1 and 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to stone elimination in days in patients with spontaneous elimination (quantitative criterion)</measure>
    <time_frame>between day 1 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain using Visual Analogue Scale</measure>
    <time_frame>days 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous stone elimination rate</measure>
    <time_frame>days 1, 7, 14, 21, 28, 35, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous stone elimination rate, according to stone size (2-3 mm, 4-5 mm, 6-7 mm)</measure>
    <time_frame>days 1, 7, 14, 21, 28, 35, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of need for surgery</measure>
    <time_frame>Within 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgery in days in patients with surgical elimination</measure>
    <time_frame>between day 1 and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pain recurrences</measure>
    <time_frame>within 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first recurrence in days</measure>
    <time_frame>between day 1 and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of need for corticoids or morphine</measure>
    <time_frame>Within 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first administration of corticoids or morphine in days</measure>
    <time_frame>between day 1 and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>Within 42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Ureterolithiasis</condition>
  <condition>Ureteral Calculi</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult over 18 years

          -  Emergency admission for a ureteral colic

          -  Radio-opaque ureterolithiasis

          -  Stone of 2 to 7 mm diameter

          -  Informed written consent

        Exclusion Criteria:

          -  Pregnancy or breast-feeding

          -  Treatment with alpha or beta-blocker

          -  Contraindication to tamsulosin (orthostatic hypertension, hepatic failure)

          -  Complication needing surgery

          -  Calculi spontaneous passage before randomization

          -  Patient not available for a 6 week follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Guillé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Urologie- Hôpital du Val de Grâce</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - Hôpital de La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Redon</name>
      <address>
        <city>Redon</city>
        <zip>35600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie- Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie- Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urologie - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. Int J Urol. 2005 Jul;12(7):615-20.</citation>
    <PMID>16045553</PMID>
  </reference>
  <reference>
    <citation>Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs. 1996 Dec;52(6):883-98. Review.</citation>
    <PMID>8957159</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <name_title>Direction of Clinical Research</name_title>
    <organization>Rennes University Hospital</organization>
  </responsible_party>
  <keyword>Ureterolithiasis</keyword>
  <keyword>Alpha1-blocker</keyword>
  <keyword>Lower ureteral stone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

